Loading data for VSTM — first visit, this takes a few seconds.
Verastem Inc. (VSTM)
NasdaqCM: VSTM
· Real-Time Price · USD
7.33
-0.10 (-1.35%)
At close: Aug 19, 2026, 8:00 PM
7.36
+0.89%
After-hours: 6:04 PM
Verastem Inc. (VSTM) Stock Price, Analysis & Data
-1.35% (1D)
No data available
| Bid | 7.4 |
| Market Cap | 660.66M |
| Revenue (ttm) | 87.53M |
| Net Income (ttm) | -202.7M |
| Beta | 0.29 |
| EPS (ttm) | -2.44 |
| PE Ratio (ttm) | n/a |
| Forward PE | -9.73 |
| P/B (ttm) | 7.84 |
| P/S (ttm) | 7.55 |
| Earnings Date | Nov 3, 2026 |
| Ask | 8.5 |
| Volume | 1,234,178 |
| Avg. Volume (20D) | 2,557,829 |
| Open | 7.65 |
| Previous Close | 7.43 |
| Day's Range | 7.33 - 7.85 |
| 52-Week Range | 3.43 - 11.25 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About VSTM
Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, which is an orally administered, small molecule dual RAF/MEK inhibitor developed to block MEK kinase activity and the compensatory reactivation of MEK by upstream RAF, thereby targeting the RAS/MAPK signaling pathway that is commonly activated in v...
Industry Biotechnology
Sector Healthcare
IPO Date Jan 27, 2012
Employees 102
Stock Exchange NasdaqCM
Ticker Symbol VSTM
Website https://www.verastem.com
Financial Performance
In 2025, Verastem's revenue was 30.91M, an increase of 209.14% compared to the previous year's 10M. Earnings were -209.47M, an increase of 60.35%.
Financial StatementsEarnings Surprise
Verastem has released their quarterly earnings on Aug 6, 2026:
Verastem Inc. is scheduled to release its earnings on Nov 3, 2026, during market hours.
Analysts project revenue of ... Upgrade
Analysts project revenue of ... Upgrade
Page 1 of 2